Cargando…
2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
BACKGROUND: The respiratory syncytial virus (RSV) fusion glycoprotein (F) is a molecule that fuses the viral and host cell membranes during virus entry as it rearranges from a meta-stable prefusion to a stable postfusion conformation. Using structure-guided design, Pfizer engineered a prefusion RSV...
Autores principales: | Schmoele-Thoma, Beate, Falsey, Ann R, Walsh, Edward E, Swanson, Kena, Zareba, Agnieszka, Cooper, David, Gruber, William C, Jansen, Kathrin U, Radley, David, Scott, Daniel, Dormitzer, Philip R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809502/ http://dx.doi.org/10.1093/ofid/ofz360.2432 |
Ejemplares similares
-
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine
por: Walsh, Edward E, et al.
Publicado: (2021) -
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine
por: Falsey, Ann R, et al.
Publicado: (2021) -
1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023) -
2781. Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers
por: Cai, Bing, et al.
Publicado: (2019) -
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine
por: Peterson, James T, et al.
Publicado: (2021)